The impact of physical activity on psychosocial outcomes in men receiving androgen deprivation therapy for prostate cancer: A systematic review

Health Psychology

Volumn 33, Issue 11, 2014, Pages 1288-1297

  Chipperfield, Kelly ^a   Brooker, Joanne ^a   Fletcher, Jane ^a   Burney, Sue ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

androgen deprivation therapy; physical activity; prostate cancer; quality of life

Indexed keywords

ANDROGEN DEPRIVATION THERAPY; ANXIETY; ARTICLE; COGNITION; DEPRESSION; DYSPNEA; FATIGUE; HUMAN; MALE; PHYSICAL ACTIVITY; PROSTATE CANCER; PSYCHOTHERAPY; QUALITY OF LIFE; RESISTANCE TRAINING; SHORT FORM 36; SOCIAL PSYCHOLOGY; SYSTEMATIC REVIEW; COGNITION DISORDERS; MOTOR ACTIVITY; PREVENTION AND CONTROL; PROSPECTIVE STUDY; PROSTATIC NEOPLASMS; PSYCHOLOGY; TREATMENT OUTCOME;

ANTIANDROGEN;

ANDROGEN ANTAGONISTS; ANXIETY; COGNITION DISORDERS; DEPRESSION; HUMANS; MALE; MOTOR ACTIVITY; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 84925940825     PISSN: 02786133     EISSN: 19307810     Source Type: Journal    
DOI: 10.1037/hea0000006     Document Type: Article

References (59)

1. Alibhai, S. M. H., Gogov, S., Allibhai, Z. (2006). Long-term side effects of androgen deprivation therapy in men with non-metastatic prostate cancer: A systematic literature review. Critical Reviews in Oncology/ Hematology, 60, 201-215. doi:10.1016/j.critrevonc.2006.06.006
2. Almeida, O. P., Waterreus, A., Spry, N., Flicker, L., Martins, R. N. (2004). One year follow-up study of the association between chemical castration, sex hormones, beta-amyloid, memory and depression in men. Psychoneuroendocrinology, 29, 1071-1081. doi:10.1016/j.psyneuen .2003.11.002
3. Andrykowski, M. A., Schmidt, J. E., Salsman, J. M., Beacham, A. O., Jacobsen, P. B. (2005). Use of a case definition approach to identify cancer-related fatigue in women undergoing adjuvent therapy for breast cancer. Journal of Clinical Oncology, 23, 6613-6622. doi:10.1200/JCO .2005.07.024
4. Barrett-Connor, E., Goodman-Gruen, D., Patay, B. (1999). Endogenous sex hormones and cognitive function in older men. Journal of Clinical Endocrinology & Metabolism: Clinical and Experimental, 84, 3681- 3685. doi:10.1210/jc.84.10.3681
5. Baumann, F. T., Zopf, E. M., Bloch, W. (2012). Clinical exercise interventions in prostate cancer patients-a systematic review of randomized controlled trials. Supportive Care in Cancer, 20, 221-233. doi: 10.1007/s00520-011-1271-0
6. Bria, E., Cuppone, F., Giannarelli, D., Milella, M., Ruggeri, E. M., Sperduti, I., Carlini, P. (2009). Does hormone treatment added to radiotherapy improve outcome in locally advanced prostate cancer?: Meta-analysis of randomized trials. Cancer, 115, 3446-3456. doi: 10.1002/cncr.24392
7. Cherrier, M. M., Asthana, S., Plymate, S., Baker, L., Matsumoto, A. M., Peskind, E., Craft, S. (2001). Testosterone supplementation improves spatial and verbal memory in healthy older men. Neurology, 57, 80-88. doi:10.1212/WNL.57.1.80
8. Cherrier, M. M., Aubin, S., Higano, C. (2009). Cognitive and mood changes in men undergoing intermittent combined androgen blockade for non-metastatic prostate cancer. Psycho-Oncology, 18, 237-247. doi: 10.1002/pon.1401
9. Cochrane Consumers and Communication Review Group. (2012). Data extraction template for Cochrane reviews. Retrieved from http://www .latrobe.edu.au/chcp/cochrane/resources.html
10. Conn, V. S., Hafdahl, A. R., Porock, D. C., McDaniel, R., Nielsen, P. J. (2006). A meta-analysis of exercise interventions among people treated for cancer. Supportive Care in Cancer, 14, 699-712. doi:10.1007/ s00520-005-0905-5
11. Cotman, C. W., Berchtold, N. C. (2002). Exercise: A behavioral intervention to enhance brain health and plasticity. Trends in Neurosciences, 25, 295-301. doi:10.1016/S0166-2236(02)02143-4
12. Cotman, C. W., Engesser-Cesar, C. (2002). Exercise enhances and protects brain function. Exercise and Sport Sciences Reviews, 30, 75-79. doi:10.1097/00003677-200204000-00006
13. Couper, J. W., Love, A. W., Dunai, J. V., Duchesne, G. M., Bloch, S., Costello, A. J., Kissane, D. W. (2009). The psychological aftermath of prostate cancer treatment choices: A comparison of depression, anxiety and quality of life outcomes over the 12 months following diagnosis. Medical Journal of Australia, 190, S86-S89.
14. Culos-Reed, S. N., Robinson, J. L., Lau, H., O'Connor, K., Keats, M. R. (2007). Benefits of a physical activity intervention for men with prostate cancer. Journal of Sport & Exercise Psychology, 29, 118-127.
15. Culos-Reed, S. N., Robinson, J. W., Lau, H., Stephenson, L., Keats, M., Norris, S., Faris, P. (2010). Physical activity for men receiving androgen deprivation therapy for prostate cancer: Benefits from a 16- week intervention. Supportive Care in Cancer, 18, 591-599. doi: 10.1007/s00520-009-0694-3
16. Dacal, K., Sereika, S. M., Greenspan, S. L. (2006). Quality of life in prostate cancer patients taking androgen deprivation therapy. Journal of the American Geriatrics Society, 54, 85-90. doi:10.1111/j.1532-5415 .2005.00567.x
17. Denkinger, M. D., Nikolaus, T., Denkinger, C., Lukas, A. (2012). Physical activity for the prevention of cognitive decline: Current evidence from observational and controlled studies. Zeitschrift fur Gerontologie und Geriatrie, 45, 11-16. doi:10.1007/s00391-011-0262-6
18. Dunn, A. L., Trivedi, M. H., O'Neal, H. A. (2001). Physical activity dose-response effects on outcomes of depression and anxiety. Medicine & Science in Sports & Exercise, 33, S587-S597.
19. Fowler, F. J., McNaughton-Collins, M., Walker-Corkery, E., Elliott, D. B., Barry, M. J. (2002). The impact of androgen deprivation on quality of life after radical prostatectomy for prostate carcinoma. Cancer, 95, 287-295. doi:10.1002/cncr.10656
20. Galvao, D. A., Nosaka, K., Taaffe, D. R., Peake, J., Spry, N., Suzuki, K., Newton, R. U. (2008). Endocrine and immune responses to resistance training in prostate cancer patients. Prostate Cancer & Prostatic Diseases, 11, 160-165. doi:10.1038/sj.pcan.4500991
21. Galvao, D. A., Nosaka, K., Taaffe, D. R., Spry, N., Kristjanson, L. J., McGuigan, M. R., Newton, R. U. (2006). Resistance training and reduction of treatment side effects in prostate cancer. Medicine and Science in Sports and Exercise, 38, 2045-2052. doi:10.1249/01.mss .0000233803.48691.8b
22. Galvao, D. A., Taaffe, D. R., Spry, N., Joseph, D., Newton, R. U. (2010). Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: A randomized controlled trial. Journal of Clinical Oncology, 28, 340-347. doi:10.1200/JCO.2009.23.2488
23. Galvao, D. A., Taaffe, D. R., Spry, N., Joseph, D., Newton, R. U. (2011). Acute versus chronic exposure to androgen suppression for prostate cancer: Impact on the exercise response. Journal of Urology, 186, 1291-1297. doi:10.1016/j.juro.2011.05.055
24. Galvao, D. A., Taaffe, D. R., Spry, N., Newton, R. U. (2007). Exercise can prevent and even reverse adverse effects of androgen suppression treatment in men with prostate cancer. Prostate Cancer & Prostatic Diseases, 10, 340-346. doi:10.1038/sj.pcan.4500975
25. Green, H. J., Pakenham, K. I., Headley, B. C., Yaxley, J., Nicol, D. L., Mactaggart, P. N., Gardiner, R. A. (2002). Altered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing hormone analogues and cyproterone acetate: A randomized controlled trial. BJU International, 90, 427-432. doi:10.1046/j.1464-410X.2002 .02917.x
26. Green, H. J., Pakenham, K. I., Headley, B. C., Yaxley, J., Nicol, D. L., Mactaggart, P. N., Gardiner, R. A. (2004). Quality of life compared during pharmacological treatments and clinical monitoring for nonlocalized prostate cancer: A randomized controlled trial. BJU International, 93, 975-979. doi:10.1111/j.1464-410X.2004.04763.x
27. Hansen, P. A., Dechet, C. B., Porucznik, C. A., LaStayo, P. C. (2009). Comparing eccentric resistance exercise in prostate cancer survivors on and off hormone therapy: A pilot study. PM & R, 1, 1019-1024. doi: 10.1016/j.pmrj.2009.09.016
28. Herr, H. W., O'Sullivan, M. (2000). Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy. Journal of Urology, 163, 1743-1746. doi:10.1016/S0022- 5347(05)67533-7
29. Higgins, J. P. T., Altman, D. G., J. A. C. Sterne (Eds.). (2011). Assessing risk of bias in included studies (Chapter 8). In J. P. T. Higgins & S. Green (Eds.), Cochrane handbook for systematic reviews of interventions (pp. 8.1- 8.50). England: John Wiley & Sons Ltd. The Cochrane Collaboration. Available from www.cochrane-handbook.org
30. Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., Forman, D. (2011). Global cancer statistics. CA: A Cancer Journal for Clinicians, 61, 69-90. doi:10.3322/caac.20107
31. Jenkins, V. A., Bloomfield, D., Shilling, V., Edginton, T. (2005). Does neoadjuvant hormone therapy for early prostate cancer affect cognition? Results from a pilot study. BJU International, 96, 48-53. doi:10.1111/ j.1464-410X.2005.05565.x
32. Keating, N. L., O'Malley, J., Smith, M. R. (2006). Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. Journal of Clinical Oncology, 24, 4448-4456. doi:10.1200/JCO .2006.06.2497
33. Kenfield, S. A., Stampfer, M. J., Giovannucci, E., Chan, J. M. (2011). Physical activity and survival after prostate cancer diagnosis in the health professionals follow-up study. Journal of Clinical Oncology, 29, 726-732. doi:10.1200/JCO.2010.31.5226
34. Keogh, J. W. L., Shepherd, D., Krägeloh, C. U., Ryan, C., Masters, J., Shepherd, G., MacLeod, R. (2010). Predictors of physical activity and quality of life in New Zealand prostate cancer survivors undergoing androgen-deprivation therapy. New Zealand Medical Journal, 123, 20- 29.
35. Kirby, R. S., Patel, M. I. (2008). Fast facts: Prostate cancer (5th ed.). Oxford, UK: Health Press Limited.
36. Kraft, E. (2012). Cognitive function, physical activity, and aging: Possible biological links and implications for multimodal interventions. Aging, Neuropsychology, and Cognition, 19, 248-263. doi:10.1080/13825585 .2011.645010
37. Lage, M. J., Barber, B. L., Markus, R. A. (2007). Association between androgen-deprivation therapy and incidence of diabetes among males with prostate cancer. Urology, 70, 1104-1108. doi:10.1016/j.urology .2007.08.012
38. Lee, C. E., Kilgour, A. R., Lau, Y. K. J. (2012). Efficacy of walking exercise in promoting cognitive-psychosocial functions in men with prostate cancer receiving androgen deprivation therapy. BMC Cancer, 12, 324. doi:10.1186/1471-2407-12-324
39. Liberati, A., Altman, D. G., Tetzlaff, J., Murlow, C., Gotzsche, P. C., Ioannidis, J. P. A., Moher, D. (2009). The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. PLoS Med, 6, 1000100. doi:10.1371/journal.pmed.1000100
40. Moffat, S. D., Zonderman, A. B., Metter, E. J., Blackman, M. R., Harman, S. M., Resnick, S. M. (2002). Longitudinal assessment of serum free testosterone concentration predicts memory performance and cognitive status in elderly men. Journal of Clinical Endocrinology & Metabolism: Clinical and Experimental, 87, 5001-5007. doi:10.1210/jc.2002-020419
41. Mols, F., van de Poll-Franse, L. V., Vingerhoets, A. J. J. M., Hendrikx, A., Aaronson, N. K., Houterman, S., Essink-Bot, M. L. (2006). Longterm quality of life among Dutch prostate cancer survivors: Results of a population-based study. Cancer, 107, 2186-2196. doi:10.1002/cncr .22231
42. National Comprehensive Cancer Network. (2012). NCCN clinical practice guidelines in oncology, Version 3: Prostate cancer. Retrieved 27/10/2012, from http://www.nccn.org/professionals/physician_gls/ f_guidelines.asp#site
43. O'Connor, D. B., Archer, J., Hair, W. M., Wu, F. C. (2001). Activational effects of testosterone on cognitive function in men. Neuropsychologia, 39, 1385-1394. doi:10.1016/S0028-3932(01)00067-7
44. Pirl, W. F., Siegel, G. I., Goode, M. J., Smith, M. R. (2002). Depression in men receiving androgen deprivation therapy for prostate cancer: A pilot study. Psycho-Oncology, 11, 518-523. doi:10.1002/pon.592
45. Ringdal, G. I., Ringdal, K. (1993). Testing the EORTC Quality of Life Questionnaire on cancer patients with heterogeneous diagnoses. Quality of Life Research, 2, 129-140. doi:10.1007/BF00435732
46. Rosenblatt, D. E., Mellow, A. (1995). Depression during hormonal treatment of prostate cancer. Journal of the American Board of Family Practice, 8, 317-320.
47. Sadetsky, N., Greene, K., Cooperberg, M. R., Hubbard, A., Carroll, P. R., Satariano, W. (2011). Impact of androgen deprivation on physical well-being in patients with prostate cancer: Analysis from the CaPSURE (Cancer of the Prostate Strategic Urologic Research Endeavor) registry. Cancer, 117, 4406-4413. doi:10.1002/cncr.26064
48. Salminen, E. K., Portin, R. I., Koskinen, A., Helenius, H., Nurmi, M. (2004). Associations between serum testosterone fall and cognitive function in prostate cancer patients. Clinical Cancer Research, 10, 7575-7582. doi:10.1158/1078-0432.CCR-04-0750
49. Scherr, D., Swindle, P. W., Scardino, P. T. (2003). National Comprehensive Cancer Network guidelines for the management of prostate cancer. Urology, 61, 14-24. doi:10.1016/S0090-4295(02)02395-6
50. Schmitz, K. H., Courneya, K. S., Matthews, C., Demark-Wahnefried, W., Galvao, D. A., Pinto, B. M., Schwartz, A. L. (2010). American College of Sports Medicine roundtable on exercise guidelines for cancer survivors. Medicine & Science in Sports & Exercise, 42, 1409-1426. doi:10.1249/MSS.0b013e3181e0c112
51. Segal, R. J., Reid, R. D., Courneya, K. S., Malone, S. C., Parliament, M. B., Scott, C. G., Wells, G. A. (2003). Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. Journal of Clinical Oncology, 21, 1653-1659. doi:10.1200/JCO.2003.09.534
52. Shahinian, V. B., Kuo, Y. F., Freeman, J. L., Goodwin, J. S. (2006). Risk of the "androgen deprivation syndrome" in men receiving androgen deprivation for prostate cancer. Archives of Internal Medicine, 166, 465-471.
53. Sharifi, N., Gulley, J. L., Dahut, W. L. (2005). Androgen deprivation therapy for prostate cancer. The Journal of the American Medical Association, 294, 238-244. doi:10.1001/jama.294.2.238
54. Steffen, T. M., Hacker, T. A., Mollinger, L. (2002). Age- and genderrelated test performance in community-dwelling elderly people: Sixminute walk test, berg balance scale, timed up & go test, and gait speeds. Physical Therapy, 82, 128-137.
55. Taylor, L. G., Canfield, S. E., Du, X. L. (2009). Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer. Cancer, 115, 2388-2399. doi:10.1002/cncr.24283
56. Thorsen, L., Courneya, K. S., Stevinson, C., Fossa, S. D. (2008). A systematic review of physical activity in prostate cancer survivors: Outcomes, prevalence, and determinants. Supportive Care in Cancer, 16, 987-997. doi:10.1007/s00520-008-0411-7
57. United States Department of Health and Human Services. (2013). PROMIS: Dynamic tools to measure health outcomes from the patient perspective. Retrieved 2/4/2013, from http://www.nihpromis.org
58. Voss, M. W., Nagamatsu, L. S., Liu-Ambrose, T., Kramer, A. F. (2011). Exercise, brain, and cognition across the life span. Journal of Applied Physiology, 111, 1505-1513. doi:10.1152/japplphysiol.00210.2011
59. Warburton, D. E. R., Nicol, C. W., Bredin, S. S. D. (2006). Health benefits of physical activity: The evidence. CMAJ, 174, 801-809. doi: 10.1503/cmaj.051351